As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
32 Analysts have issued a Innovent Biologics forecast:
32 Analysts have issued a Innovent Biologics forecast:
Dec '24 |
+/-
%
|
||
Revenue | 10,312 10,312 |
52%
52%
|
|
Gross Profit | 8,659 8,659 |
56%
56%
|
|
EBITDA | 179 179 |
122%
122%
|
EBIT (Operating Income) EBIT | -280 -280 |
77%
77%
|
Net Profit | -104 -104 |
91%
91%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.
Head office | China |
Employees | 5,659 |
Website | www.innoventbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.